atorvastatin + choline fenofibrate

**Atorvastatin + choline fenofibrate** is a fixed-dose combination of two small molecule lipid-modifying agents: atorvastatin, a statin that inhibits HMG-CoA reductase to lower LDL cholesterol, and choline fenofibrate, a hydrophilic salt of fenofibric acid (the active form of fenofibrate), which activates peroxisome proliferator-activated receptor alpha (PPAR-alpha) to lower triglycerides and increase HDL cholesterol. This combination is used primarily for the management of mixed dyslipidemia and to reduce cardiovascular risk in patients (especially with type 2 diabetes) who have elevated triglycerides and cholesterol that are not controlled by statin monotherapy. Choline fenofibrate provides similar efficacy and tolerability compared to micronized fenofibrate but is more hydrophilic, which may influence absorption. The combination is taken as an oral tablet, and clinical trials indicate a significant improvement in lipid profile (decreased triglycerides and LDL, increased HDL) relative to monotherapy, with an overall favorable safety profile for fenofibrate-based statin combinations.

Other names

atorvastatin/choline fenofibrateatorvastatin with choline fenofibrate